Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-32.72 Insider Own6.04% Shs Outstand0.44M Perf Week-22.65%
Market Cap1.12M Forward P/E- EPS next Y-4.61 Insider Trans0.00% Shs Float0.42M Perf Month-48.43%
Income-8.69M PEG- EPS next Q-3.79 Inst Own1.13% Short Float6.07% Perf Quarter-57.24%
Sales0.00M P/S- EPS this Y59.63% Inst Trans- Short Ratio1.16 Perf Half Y-75.34%
Book/sh8.58 P/B0.30 EPS next Y71.49% ROA-120.05% Short Interest0.03M Perf Year-90.22%
Cash/sh10.75 P/C0.24 EPS next 5Y- ROE-146.08% 52W Range3.00 - 30.30 Perf YTD-72.10%
Dividend Est.- P/FCF- EPS past 5Y26.37% ROI-228.17% 52W High-91.58% Beta0.82
Dividend TTM- Quick Ratio3.78 Sales past 5Y0.00% Gross Margin- 52W Low-14.91% ATR (14)0.52
Dividend Ex-Date- Current Ratio3.78 EPS Y/Y TTM81.04% Oper. Margin0.00% RSI (14)28.21 Volatility19.37% 16.66%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q79.29% Payout- Rel Volume12.56 Prev Close3.14
Sales Surprise- EPS Surprise91.30% Sales Q/Q- EarningsMay 15 AMC Avg Volume21.88K Price2.55
SMA20-28.80% SMA50-44.51% SMA200-70.69% Trades Volume274,783 Change-18.84%
May-17-24 08:30AM
May-15-24 10:54PM
May-13-24 07:23AM
Apr-03-24 07:00AM
07:00AM Loading…
Apr-02-24 07:00AM
Mar-27-24 04:05PM
Mar-21-24 10:53PM
Feb-07-24 07:00AM
Feb-06-24 07:00AM
Feb-01-24 09:00AM
Jan-05-24 08:31AM
Jan-04-24 04:05PM
Dec-20-23 04:05PM
09:06AM Loading…
Nov-17-23 09:06AM
Nov-16-23 01:30PM
Nov-09-23 04:05PM
Oct-26-23 09:00AM
Aug-31-23 09:00AM
Aug-10-23 04:15PM
Jun-27-23 09:00AM
Jun-13-23 04:15PM
Jun-08-23 09:00AM
May-26-23 04:00PM
May-24-23 08:00AM
May-11-23 04:05PM
May-10-23 11:46AM
Apr-21-23 12:02PM
06:00AM Loading…
Apr-20-23 06:00AM
Mar-20-23 04:30PM
Mar-16-23 01:15PM
Feb-21-23 04:05PM
Dec-05-22 08:30AM
Nov-10-22 05:20PM
Sep-06-22 09:00AM
Aug-24-22 04:05PM
Aug-15-22 04:05PM
Jun-13-22 09:00AM
May-23-22 09:00AM
May-16-22 04:05PM
Apr-25-22 04:50PM
Apr-21-22 09:00AM
Mar-28-22 08:30AM
Mar-24-22 08:30AM
Feb-10-22 07:27AM
Feb-07-22 08:58AM
Jan-13-22 08:30AM
Jan-05-22 08:30AM
Nov-22-21 05:06AM
Nov-19-21 02:17PM
Nov-17-21 08:00AM
Nov-15-21 04:01PM
Nov-12-21 08:00AM
Nov-11-21 06:00AM
Oct-19-21 07:00AM
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.